Sanofi joins hands with Prellis Biologics

"The EXIS platform provides an unparalleled ability to recreate lymph node organoids in vitro. This powerful technology enables investigation of human B- and T-cell responses for a variety of applications, including antibody discovery and therapeutic immunogenicity," said Melanie P. Matheu, PhD, Founder and CEO of Prellis Biologics. "We are delighted to work in collaboration with Sanofi in novel antibody research with our differentiated approach."

"Recreating the human immune response and breaking tolerance to human antigens, in the EXIS platform allows us to rapidly identify an expansive set of high-quality antibodies," said Kevin Chapman, PhD and CSO of Prellis.

Read Also - Wockhardt , Serum Life Sciences collaborate for manufacturing multiple vaccines

Prellis Biologics, Inc. is a privately held company based in the San Francisco Bay Area, CA.

Prellis Biologics, Inc. utilizes its proprietary, high-resolution bioprinting technology to recreate and engineer human tissues in vitro. A key application is Prellis' Externalized Immune System, EXIS, which through the creation of lymph node organoids (LNOs) precisely reproduces the human immune response in vitro. With EXIS, Prellis is able to exploit fully-human immune responses for a variety of applications, including antibody discovery, immunogenicity screening, and T-cell epitope discovery, amongst others.

Read Also - AstraZeneca, Honeywell to collaborate to develop next-generation respiratory inhalers